NOVEL CLASS OF MONOSPECIFIC AND BISPECIFIC HUMANIZED ANTIBODIES THAT TARGET THE INSULIN-LIKE GROWTH FACTOR TYPE I RECEPTOR (IGF-1R)

摘要

The present invention provides compositions and methods of use of anti-IGF-1R antibodies or fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R; effectively neutralize activation of IGF-1R by IGF-1 in intact cells; block binding of R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (seq id no:3) and light chain CDR sequences KASQEVGTAVA (seq id no:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.